MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/mr/roac020

Медицинская библиотека · Modern rheumatology · 2023

Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.

Ishiguro Naoki, Tanaka Yoshiya, Matsubara Tsukasa, Atsumi Tatsuya, Amano Koichi, Sugiyama Eiji, Yamaoka Kunihiro, Winthrop Kevin, Kivitz Alan, Burmester Gerd R, Gottenberg Jacques-Eric, Genovese Mark C, Matzkies Franziska, Guo Ying, Jiang Deyuan, Bartok Beatrix, Pechonkina Alena, Kondo Akira, Besuyen Robin, Takeuchi Tsutomu

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

Characterize safety of the Janus kinase-1 preferential inhibitor filgotinib (FIL) in Japanese patients with moderately to severely active rheumatoid arthritis (RA).

METHODS

Data from three Phase 3 trials (NCT02889796, NCT02873936, and NCT02886728) and a long-term extension (NCT03025308) through September 2019 were integrated; patients received ≥1 dose of FIL 200 (FIL200) or 100 mg (FIL100) daily, or placebo (PBO). We calculated exposure-adjusted incidence rates (EAIRs) per 100 patient-years FIL exposure (100PYE) for treatment-emergent adverse events (TEAEs) and adverse events of special interest.

RESULTS

Among 3691 total patients and 6080.7 PYE, 229 Japanese patients received FIL for 311.4 PYE (median 1.5, maximum 2.5 years). During the 12-week PBO-controlled period, serious TEAEs and TEAEs leading to study drug disruption were comparable between FIL and PBO. Serious infection rates were 1.9%, 0%, and 2% for FIL200, FIL100, and PBO during the PBO-controlled period; long-term FIL200 and FIL100 EAIRs were 3.8 and 2.1/100PYE. No herpes zoster (HZ) or major adverse cardiovascular events (MACEs) occurred during the PBO-controlled period; long-term FIL200 and FIL100 EAIRs were 3.0 and 2.1/100PYE (HZ) and 0.6 and 0/100PYE (MACE).

CONCLUSION

Long-term FIL treatment (median 1.5, maximum 2.5 years exposure) was well tolerated at 100- and 200-mg doses in Japanese patients with RA.

Для цитирования: Ishiguro Naoki, Tanaka Yoshiya, Matsubara Tsukasa, Atsumi Tatsuya, Amano Koichi, Sugiyama Eiji, Yamaoka Kunihiro, Winthrop Kevin, Kivitz Alan, Burmester Gerd R, Gottenberg Jacques-Eric, Genovese Mark C, Matzkies Franziska, Guo Ying, Jiang Deyuan, Bartok Beatrix, Pechonkina Alena, Kondo Akira, Besuyen Robin, Takeuchi Tsutomu. Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.. Modern rheumatology. 2023. DOI: 10.1093/mr/roac020.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.